US Stock MarketDetailed Quotes

AMLX Amylyx Pharmaceuticals

Watchlist
  • 4.070
  • +0.070+1.75%
Close Dec 26 16:00 ET
278.99MMarket Cap-1.07P/E (TTM)

About Amylyx Pharmaceuticals Company

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Company Profile

SymbolAMLX
Company NameAmylyx Pharmaceuticals
Listing DateJan 7, 2022
Issue Price19.00
Founded2013
MarketNASDAQ
Employees384
Fiscal Year Ends12-31
Address43 Thorndike Street
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02141
Phone1-617-682-0917
Websitehttp://www.amylyx.com

Company Executives

  • Name
  • Position
  • Salary
  • Justin Klee
  • Co-Chief Executive Officer and Director
  • 7.42M
  • Joshua Cohen
  • Co-Chief Executive Officer and Director
  • 7.42M
  • James M. Frates
  • Chief Financial Officer and Principal Accounting Officer
  • 3.51M
  • Dr. Camille L. Bedrosian,M.D.
  • Chief Medical Officer
  • 2.37M
  • Gina M. Mazzariello
  • Chief Legal Officer and General Counsel
  • 3.01M
  • Dr. George Mclean Milne, Jr,PhD
  • Chairman of the Board
  • 385.07K
  • Dr. Bernhardt G. Zeiher, F.A.C.P.,F.C.C.P.,M.D.
  • Director
  • --
  • Paul Fonteyne, M.S.
  • Independent Director
  • 342.12K
  • Daphne E. Quimi
  • Independent Director
  • 348.59K
  • Karen Firestone
  • Independent Director
  • 681.15K
Heat List
US
Overall
Symbol
Price
% Chg

No Data